Age: 70.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Biopsy, Condition aggravated, Joint instability, Lymphadenopathy, Lymphoma
Clinical narrative: Lymphoma; Lymphoma aggravated; Joint Instability; Lymph node disorder; This spontaneous case was reported by a health care professional and describes the occurrence of LYMPHOMA (Lymphoma) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    The patient's past medical history included Tobacco user (Half a pack of cigarette sticks a day) from 1964 to 1985, Alcohol use (A glass of wine, Beer occasionally.) in 1968, Pinched nerve and Swelling of legs. Family history included Breast cancer and Colon cancer. Concurrent medical conditions included Sulfonamide allergy (Manifested by Hives), Drug allergy (Allergic to Artificial tear ointment Manifested by face all broke out.), Drug allergy (Allergic to quinine manifested by High Fever and Hives.), Drug allergy (Allergic to hydrocodone manifested by swelling.), Drug allergy (Allergic to Percocet manifested by Swelling.), Drug allergy (Allergic to Clonazepam manifested by swelling.), Allergy to antibiotic (Allergic to Amoxicillin manifested by Hives.), Penicillin allergy (Manifested by Hives), Drug allergy (Allergic to Omeprazole manifested by Rash.) and Lymphoma. Concomitant products included PANTOPRAZOLE for Acid reflux (esophageal), ATORVASTATIN for Blood cholesterol, LOSARTAN for Blood pressure high, ALLOPURINOL for Gout, PROCHLORPERAZINE for Nausea, ONDANSETRON for Nausea and Vomiting, TRAZODONE for Sleep disorder NOS, COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]) for Supplementation therapy, MONTELUKAST for an unknown indication.   In 2017, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) .4 ml once a day. On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In March 2021, the patient experienced LYMPHOMA (Lymphoma) (seriousness criteria hospitalization and medically significant), JOINT INSTABILITY (Joint Instability) and LYMPHADENOPATHY (Lymph node disorder). On 23-Mar-2021, the patient experienced CONDITION AGGRAVATED (Lymphoma aggravated). The patient was hospitalized on 23-Mar-2021 due to LYMPHOMA. At the time of the report, LYMPHOMA (Lymphoma), CONDITION AGGRAVATED (Lymphoma aggravated), JOINT INSTABILITY (Joint Instability) and LYMPHADENOPATHY (Lymph node disorder) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In March 2021, Biopsy: confirmed lymphoma cancer Confirmed Lymphoma Cancer. In March 2021, Magnetic resonance imaging: found lymph nodes at the back (Inconclusive) Found lymph nodes at the back. On 22-Mar-2021, Scan: abnormal (abnormal) Confirmed Lymphoma Cancer.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   In 2020, the patient experienced PINCH NERVE and LEG SWELLING. In 2020, the PINCH NERVE resolved.   Treatment information included Chemotherapy.  Action taken with mRNA-1273 in response to event was not applicable.  Regarding Lymphoma, the event is assessed as unlikely related to mRNA-1273 based upon the biological feasibility and unlikely temporal association. Regarding other events, very limited information has been provided at this time. Further information has been requested.; Sender's Comments: Regarding Lymphoma, the event is assessed as unlikely related to mRNA-1273 based upon the biological feasibility and unlikely temporal association. Regarding other events, very limited information has been provided at this time. Further information has been requested.